Total revenues

Alnylam Pharmaceuticals·Products & Services·15 segments·Rolls up to Total Revenue

Breakdown

Segment	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
AMVUTTRA	$230.11M	$258.59M	$286.51M	$309.99M	$491.95M	$685.3M	$826.59M	$889.93M
GIVLAARI	$62.13M	$71.04M	$64.65M	$66.97M	$80.85M	$73.87M	$86.8M	$74.39M
OXLUMO	$40.61M	$40.22M	$43.57M	$42.09M	$46.87M	$52.83M	$49.65M	$51.32M
ONPATTRO	$77.24M	$50.29M	$56.1M	$49.49M	$52.54M	$39.08M	$31.69M	$20.48M
Total	$659.83M	$500.92M	$593.17M	$594.19M	$773.69M	$1.25B	$1.1B	$1.17B

Net product revenuesView metric

Net revenues from collaborationsView metric

Royalty revenueView metric

Roche Development Services ObligationView metric

Research Services ObligationView metric

C5 License ObligationView metric

Regeneron Technology Transfer ObligationView metric

Other license programsView metric